Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, the 10 stocks below are the highest rated in the biotech industry.
CAPS contains more than just the crowd's opinions. The votes of CAPS' best-performing members, known as All-Stars, count more in shaping each company's rating than do the picks of their poorer-performing peers. That way, investors can intelligently use members' collective wisdom to make better decisions.
Repligen gets a green thumb for flirting with the one year low on lousy results of their phase III trial of secretin as an adjunct for pancreatic MRI. Disappointing I guess, but I don't know about a 20% haircut on a stock already down 15% from recent highs. The company will likely continue to maintain cash flows even through anemic 5M quarterly revenues and lazy spending on the phase IIb trial of (yawn) uridine for bipolar disorder. Is this the most boring baby biotech around? Possibly.
Here are the rest of the 10 highest-rated companies in the industry along with their CAPS rating:
CAPS Rating (out of 5)
Market Cap (in millions)
Astex Pharmaceuticals (NAS: ASTX)
Aeterna Zentaris (NAS: AEZS)
Emergent BioSolutions (NYS: EBS)
Gilead Sciences (NAS: GILD)
Spectrum Pharmaceuticals (NAS: SPPI)
PDL BioPharma (NAS: PDLI)
Source: Motley Fool CAPS as of Nov. 7, 2011.
Use the table as a first step to help generate ideas for further research. Having a watchlist of promising companies is a great place to start. We can help you keep tabs on these beloved companies with My Watchlist, our free, personalized stock tracking service. Click here to start now.
At the time thisarticle was published Fool contributor Dan Dzombak can be found on his Twitter account: @dandzombak. Click here to see his holdings and a short bio.Motley Fool newsletter services have recommended buying shares of Gilead Sciences, Emergent BioSolutions, and BioMarin Pharmaceutical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.